Alliance A021602/CABINET NETs
Alliance A021602/CABINET: Phase III Trial Evaluating Cabozantinib vs Placebo for Advanced Neuroendocrine Tumors After Disease Progression on 1 or More Therapies

Released: October 27, 2023

Activity

Progress
1
Course Completed